Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes: Time for Endocrinologists to Take Action
Saturday, May 9, 2020
3:15 PM – 4:00 PM
Participants should be aware of the following financial/non-financial relationships: Kenneth Cusi, MD, FACE: Disclosure information not submitted. W. Timothy Garvey, MD: Disclosure information not submitted.
Discuss the disease burden and the role of type 2 diabetes mellitus in the development of steatohepatitis and cirrhosis.
Describe the diagnostic pathways for NAFLD.
Review current treatment options and the upcoming drugs in the research pipeline.